Cost-effectiveness analyses
Significant changes in the financing
and delivery of health-care services, in the U.S. as well as abroad,
have heightened the demand for information on the cost-effectiveness
of new products. PAI has been a pioneer in the design and conduct
of cost-effectiveness analyses for the pharmaceutical and biotechnology
industries since the early 1980s. Our track record of publications in
this area is extensive, including studies of the cost-effectiveness
of COREG® (carvedilol), OXYCONTIN® (oxycodone
sustained-release), PREVNAR® (pneumococcal
conjugate vaccine), MEVACOR® (lovastatin),
NICORETTE® (nicotine polacrilex), TICLID® (ticlopidine),
VARIVAX® (varicella vaccine), LOVENOX® (enoxaparin),
and PULMOZYME® (rhDNase), to name only a few.
|
|
|
